Investigation of Novel Immunological Biomarkers by Mass Cytometry in P
Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 4 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Biomarkers analysis
What it measured
Main measures
Frequency of immune subpopulations
1 year
Other measures (5)
Frequency of immune subpopulations correlated to EDSS score
1 year
Disability progressionFrequency of immune subpopulations correlated to disease progression delay
1 year
Frequency of immune subpopulations correlated to disease progression events
1 year
Frequency of immune subpopulations correlated to spinal lesions
1 year
MRI lesionsProfiles of CIS+ patients
1 year
Who could take part
Early (CIS/RIS) · 18 and over
Show the full criteria
Inclusion criteria
Patients : Inclusion Criteria: * Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory) * At least 18 years of age * Diagnosed with MS according to criteria 2017 at the time of their last visit. * Non-opposition to participation in the study * Having had at least one visit in the year following collection * Follow-up for at least 1 year after collection. * Having signed the OFSEP consent
Exclusion criteria
* CIS patients with progressive MS Healthy volunteers : Inclusion Criteria: * Age 18 years or older * Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351). * Matched on age and sex to patients of interest in the OFSEP cohort * Not having objected to participation in the study Exclusion Criteria: * Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.
Papers
Loading reviews and guidelines…
Linked trials
Refers to
B Cell Differentiation in MSNot a drug-phase study · Completed
Links found where a registry record names another trial's registry number.
History
Started
Feb 2020
Main results due
Mar 2022
Finished
Mar 2022